Directed Evolution of Novel AAV Vectors for Clinical Gene Therapy
In this keynote webinar, Professor David Schaffer, Director, Berkeley Stem Cell Center, University of California, Berkeley, describes how his team has engineered AAV variants with greatly improved delivery efficiency to multiple organs, as well as targeting delivery to specific cell types and building the capacity to evade immune responses. He also provides an update on how these novel AAV variants are being deployed in eight clinical trials involving delivery to the retina, heart, and lung.
Watch NowSponsored by: ThermoFisher Scientific
Gene Therapy: Critical Quality Attributes of Viral Vector and Lipid Nanoparticle Stability
In this GEN Biotechnology webinar, Dr. Bernardo Cordovez, Founder and Chief Science Officer at Halo Labs discusses the challenges of realizing the promise of gene therapies without using large quantities of viral vector or LNP samples during the development process.
Watch NowSponsored by: Halo Labs
In Vivo Genome Editing: Engineering Effectors, Guides, and Templates
In this inaugural Keynote webinar hosted by GEN Biotechnology, Professor Erik Sontheimer presents his team’s advances in developing new CRISPR-Cas effectors, engineered guides, and enhanced templates that improve in vivo implementation across nuclease editing, base editing, and prime editing platforms.
Watch NowSponsored by: Taconic Biosciences
Delivery of mRNA Therapies: Bob Langer Discusses Past, Present, and Future
In this inaugural GEN Biotechnology webinar, distinguished guest Dr. Robert Langer, the David H. Koch Institute professor of chemical engineering at MIT and co-founder of Moderna, discusses his early research on developing controlled release systems for macromolecules, leading to the isolation of the first angiogenesis inhibitors and methods for nanoparticle-based drug delivery. He also covers the mRNA vaccine development timeline and effectiveness during the COVID-19 pandemic.
Watch NowSponsored by: ThermoFisher Scientific